Business
Curis Reports Second Quarter 2020 Financial Results
- Clinical data expected in CA-4948 NHL and AML/MDS trials by year-end - - Initiation of Phase 1 trial of CA-4948 in combination with ibrutinib in NHL
About this update from Curis, Inc.
[{"type":"text","content":"- Clinical data expected in CA-4948 NHL and AML/MDS trials by year-end -\n - Initiation of Phase 1 trial of CA-4948 in combination with ibrutinib in NHL expected in second half of 2020 -\n - Initiation of Phase 1a/1b trial of anti-VISTA monoclonal antibody, CI-8993, in advanced refractory solid tumors, expected in the second half of 2020 -\n - Management to host conference call today at 4:30 p.m. ET -\n\n\nLEXINGTON, Mass., Aug. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2020.\n\n \n \n \n \n \n \n\n \n\"Our recent accomplishments represent meaningful progress for Curis, as we advanced our clinical pipeline and achieved key financial objectives. These recent developments set us up for near-term data readouts, which we expect will provide durable momentum into 2021,\" said James Dentzer, President and Chief Executive Officer of Curis. \"In addition to advancing the ongoing Phase 1 study of our first-in-class IRAK4 inhibitor, CA-4948, in patients with non-Hodgkin's lymphoma (NHL), we initiated a new Phase 1 study of CA-4948 in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). We are particularly excited about this study, as AML and high-risk MDS are driven, in over half of patients, by the long isoform of IRAK4, which CA-4948 directly targets. Today, I am pleased to announce our plans to initiate a study of CA-4948 before the end of the year, which will evaluate CA-4948 in combination with ibrutinib, a BTK inhibitor, in patients with NHL, including those with MYD88 altered disease.\" \nMr. Dentzer continued, \"For our VISTA program, we received clearance from the U.S. Food and Drug Administration (FDA) on our Investigational New Drug (IND) application for CI-8993 to initiate a Phase 1a/1b dose-escalation study in patients with solid tumors. We look forward to building on our pipeline-wide progress and expect to report data on all three clinical studies, CA-4948 in NHL, CA-4948 in AML/MDS, and CI-8993 in solid tumors, by year-end.\"\nSecond Quarter 2020 and Recent Operational Highlights\nPrecision oncology, CA-4948 (IRAK4 Inhibitor; Aurigene collaboration):\nCuris is evaluatin...